BioSpace News Archive

NightHawk Biosciences, a fully integrated biopharmaceutical company specializing in the end-to-end development, manufacturing, and commercialization of innovative medical countermeasures that combat unmet and emerging biothreats, provided strategic, financial, and operational updates for the quarter ended June 30, 2023.

Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today second quarter 2023 financial results and highlighted recent updates.

Alaunos Therapeutics, Inc., announced financial results for the second quarter ended June 30, 2023.

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial results for the quarter ended June 30, 2023.

Acer Therapeutics Inc. reported financial results for the second quarter ended June 30, 2023 and provided a corporate update.

INVO Bioscience, Inc. announced financial results for the second quarter ended June 30, 2023 and provided a business update.

Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR) today reported financial results for the second quarter 2023 and provided a business update.

PhenomeX, Inc., a life sciences tools company, reported financial results for the second quarter ended June 30, 2023.

AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter and six months ended June 30, 2023.

Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune and autoimmune-detailed diseases, today announced second quarter 2023 results and provided a business update.